1620 Investment Advisors Inc. Takes $125,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

1620 Investment Advisors Inc. purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the fourth quarter, HoldingsChannel reports. The firm purchased 1,402 shares of the medical equipment provider’s stock, valued at approximately $125,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Geode Capital Management LLC increased its stake in shares of Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after acquiring an additional 32,551 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of Lantheus in the 3rd quarter valued at about $25,955,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Lantheus by 47.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock valued at $1,041,000 after acquiring an additional 3,772 shares during the last quarter. Empirical Asset Management LLC bought a new stake in shares of Lantheus in the 4th quarter valued at about $323,000. Finally, Focus Financial Network Inc. bought a new stake in Lantheus during the 4th quarter worth approximately $292,000. 99.06% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 64,109 shares of company stock valued at $6,110,806. 1.50% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms recently issued reports on LNTH. Truist Financial increased their target price on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. JMP Securities reissued a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. B. Riley lowered their target price on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research note on Friday. Finally, The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price for the company. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $129.43.

Lantheus Stock Down 1.2 %

Shares of LNTH opened at $97.71 on Friday. The stock has a market capitalization of $6.69 billion, a P/E ratio of 16.26 and a beta of 0.38. Lantheus Holdings, Inc. has a twelve month low of $57.92 and a twelve month high of $126.89. The company has a 50 day moving average of $92.67 and a 200-day moving average of $96.64.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.